Recent Announcements

Unique Patient Populations: Patients With Decompensated Cirrhosis

Additional revisions have been made to Unique Patient Populations: Patients With Decompensated Cirrhosis, sharpening the focus to patients with decompensated cirrhosis only. For guidance on patients with compensated cirrhosis, please refer to Initial Treatment of HCV Infection

Read More

Guidance Sections Updated

The Initial, Retreatment, Monitoring, and Unique Populations (HIV/HCV Coinfection, Cirrhosis, Post-Liver Transplantation, and Renal Impairment) sections have been extensively revised based on newly available therapies and data.

Read More

Updated When and In Whom to Initiate Therapy

The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.

Read More

US FDA Approval of Ledipasvir/Sofosbuvir

The panel is meeting and currently reviewing data to update the Guidance based on the US FDA approval of ledipasvir/sofosbuvir. The updated Guidance will be posted in early December.

Read More

Updated Introductory Statement of When and In Whom to Initiate Therapy

The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.

Read More

New Section: Management of Acute HCV Infection

The newest section of the AASLD/IDSA/IAS–USA hepatitis C Guidance, Management of Acute HCV Infection, is now available. Click here to access this section.

Read More

Updated Information on Drug Interactions

Updated information on drug interactions between simeprevir and certain immunosuppressant drugs has been added based on the manufacturer's revised product prescribing information. For more information see Unique Patient Populations.

Read More

Updated Statement on Drug-drug Interactions

Simeprevir concentration is increased by approximately 6-fold when coadministered with cyclosporine (in combination with daclatasvir [an investigational drug] and RBV). Coadministration of simeprevir with cyclosporine is not recommended. For more information see Unique Patient Populations.

Read More

New Section: When and In Whom to Initiate HCV Therapy

We are pleased to introduce the newest section of the Guidance, When and in Whom to Initiate HCV Therapy. Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure; virologic cure is expected to benefit chronically infected persons.

Read More
Top